GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptahem AB (XSAT:APTA) » Definitions » COGS-to-Revenue

Aptahem AB (XSAT:APTA) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aptahem AB COGS-to-Revenue?

Aptahem AB's Cost of Goods Sold for the three months ended in Mar. 2024 was kr-0.61 Mil. Its Revenue for the three months ended in Mar. 2024 was kr0.00 Mil.

Aptahem AB's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Aptahem AB's Gross Margin % for the three months ended in Mar. 2024 was %.


Aptahem AB COGS-to-Revenue Historical Data

The historical data trend for Aptahem AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptahem AB COGS-to-Revenue Chart

Aptahem AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptahem AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aptahem AB COGS-to-Revenue Calculation

Aptahem AB's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=-2.631 / 0
=

Aptahem AB's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=-0.609 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptahem AB  (XSAT:APTA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Aptahem AB's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - -0.609 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Aptahem AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptahem AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptahem AB (XSAT:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.

Aptahem AB (XSAT:APTA) Headlines

No Headlines